Summary
The Federal Circuit reversed a district court's holding of obviousness for claims of a patent directed to an abuse-resistant sublingual tablet (Zubsolv®) for treating opioid dependence. The court held that the challenger failed to prove obviousness by clear and convincing evidence because no prior art reference taught or suggested using citric acid as a carrier particle for buprenorphine in an interactive mixture. The Federal Circuit found the district court's analysis was tainted by hindsight bias and improperly discounted objective indicia of nonobviousness, including the formulation's unexpected 66% improvement in bioavailability while maintaining the critical 4:1 buprenorphine-to-naloxone ratio.
Holdings
- The claims are not invalid for obviousness because the prior art does not teach or suggest the specific combination of elements, and the evidence of unexpected results (66% improved bioavailability) supports nonobviousness.
Questions Presented
- Whether claims 1, 3–6, and 8–10 of U.S. Patent No. 8,940,330 are invalid for obviousness under 35 U.S.C. § 103.
Disposition
reversed_and_remanded
Cases Cited (8)
- In re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litig., 676 F.3d 1063 (Fed. Cir. 2012)(cited)
- InTouch Techs., Inc. v. VGO Commc'ns, Inc., 751 F.3d 1327 (Fed. Cir. 2014)(cited)
- KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007)(cited)
- Graham v. John Deere Co., 383 U.S. 1 (1966)(cited)
- Interconnect Planning Corp. v. Feil, 774 F.2d 1132 (Fed. Cir. 1985)(cited)
- In re Gordon, 733 F.2d 900 (Fed. Cir. 1984)(cited)
- Leo Pharm. Prods., Ltd. v. Rea, 726 F.3d 1346 (Fed. Cir. 2013)(cited)
- Orexo AB v. Actavis Elizabeth LLC, 217 F. Supp. 3d 756 (D. Del. 2016)(cited)
Cited In (0)
No citing cases on record yet.